Tirzepatide Scores Win in Second Obesity Trial, SURMOUNT-2
The "twincretin" tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.
Medscape Medical News
source https://www.medscape.com/viewarticle/991277?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/991277?src=rss
Comments
Post a Comment